IPMMA Magazine : July - September 2020

CONTENTS

An official Publica on of Indian Pharma Machinery Manufacturers’ Associa on (IPMMA) 06 Atmanirbhar Bharat - Pharma Industry Perspective

Vol 10 | Issue 3 | Jul - Sep 2020

An official Publica on of IPMMA

12 Leaders In-Sight
Babulal Singhania, Founder-Director – Singhania Tableting

Indian Pharma Machinery 16 Wisdom Nuggets by Pharma Luminaries - Troikaa Pharmaceuticals Ltd
Manufacturers’ Associa on 22 Every innovation has to benefit mankind at large
26 The Importance of Equipment Maintenance in Assuring Product Quality
PUBLISHER 32 Conducting Remote FAT (Factory Acceptance Test)
IPMMA
In Pharmaceutical Industry in a Compliance Way
EDITOR
Mahendra Mehta 38 Expert Talk - The Future of Pharma Machinery
46 Resurgence in Pharma
TRUSTEE 50 Industry Cluster - A national industry apprenticeship initiative
Bhavna Shah 50 Pharmacist as new ema executive director
Rajesh Shah 52 Mission Atma Nirbhar in pharma
Ratan Singhania
Vinod Padia

PRESIDENT
Mahendra Mehta

VICE PRESIDENT
Shehul Sheth

HON. SECRETARY
Harshit Shah

ADVISOR
Kaushik Desai

EDITORIAL SUPPORT
Harish Panchal
Parag Jawale

ACCOUNTS
Anil Kumar Mehta

CIRCULATIONS
Rajkumar Prajapati

CORRESPONDENCE ADDRESS
Indian Pharma Machinery
Manufacturers’ Associa on
(IPMMA)

20, Suyog Industrial Estate, L.B.S. Marg,
Vikhroli (West), Mumbai 400 083, INDIA

Phone No : +91-9004377743
Email: [email protected]
Web: www.ipmma.org

Opinions and information shared by the
authors of individual articles or an

advertisement do not necessarily represent
official view and endorsement by IPMMA

02 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



President's desk

Mahendra Mehta

Dear Readers,

In 2020, we all learnt a new way of working called “New Normal” and virtual connectivity gave new meaning to
connecting and even meeting new people.What we earlier saw as a shocking pandemic gradually turned out to be a
hard lesson inducing adaptability in us at a whole new level.The shock gradually tapered off so did the bruised
economy which is now recovering and gearing up.

This COVID-19 pandemic has once again rung the alarm bell on the perils of excessive import dependence on a
single country for bulk requirements of Active Pharmaceutical Ingredients (APIs) used for the production of
formulations.TheUnionCabinet adopted a decision in March 2020 for the promotion of domestic production ofAPIs
and intermediates.With government support through suitable amendments in existing policies Indian Pharma
industry is heading towards import self-reliance, now known as Atmanirbhar Bharat which could be considered as
a sub-set of the bigger vision Make in India.

IPMMA has taken yet another step in its contribution towards our nation's workforce development by forming
industrial cluster for Industry Apprenticeship Initiative (IAI) by the Ministry of Skill Development and
Entrepreneurship (MoSDE),Gov of India through DirectorateGeneralTraining.We are thankful to Mr Oswin Dsouza
for representing IPMMA in this initiative managing all the coordination. Additionally, to contribute to the
development of Industry-Academia interface, IPMMA is also working on developing a Good Engineering Practices
(GEP) document benefiting the entire Pharma Industry.

An international webinar on Future of Pharma Machinery organized by IPMMA, Cadila Pharmaceuticals and IRM
got overwhelming response.This webinar had international speakers from India, UAE, Indonesia, Malaysia and Sri
Lanka.In this edition lookout for our detailed report for the Resurgence in Pharma webinar held on 21 Aug which
included our IPMMA advisor Kaushik Desai as a panelist among other esteemed speakers. Aligning to the new
normal, we are glad to announce that IPMMA is supporting FICCI organized Global Healthcare Expo, a virtual expo
to be held on 26-28Oct 2020.

In the light of growing concern with rise in Covid-19 cases and government restrictions, with our organizing partner
MMI we've decided to postpone Pharma Pro&Pack Expo toSeptember 2021 for everybody's safety.

Aligning ourselves to the New Normal, IPMMA is also much active now on social media and dynamic website.

StaySafe,Stay Healthy!

YourTruly,

Mahendra Mehta www.ipmma.org
04 PHARMA PRO & PACK | JULY - SEPTEMBER 2020



COVER STORY Atmanirbhar Bharat:
Pharma Industry perspective

The Indian pharmaceutical industry is the world's Atmanirbhar Bharat, it has attracted many affirmative
third largest of drugs by volume and growing responses from all experts. However, let's look at this
consistently. This pandemic has given us yet initiative from manufacturer's lens what it means to
another opportunity to prove to the world that India is them and how we can collectively achieve our mission
really the Pharmacy of the World. Since the address by which could be a next step to Make in India.
our Prime Minister announcing the initiative

Shirish Belapure change the tide again. Indian pharma equipment
Principal Technical manufacturers can adopt two-pronged approach to
Consultant improve mechanical skills by either employing talent
Indian Pharmaceu cal available from European market either as a consultant
Alliance (IPA) or employing directly in senior positions as done by
Chinese Machine manufacturing industry or by
The pharma machinery manufacturing sector in India collaborating with these companies for building plants
need to keep pace with pharma manufacturing in India. Secondly, software can be improved by
technology developments. The difference in working with Indian software industry who has more
expectations of pharma formulation manufacturers than enough talent. Some Indian companies have
and the deliverable capabilities of machinery started looking at this trend and following.
manufactures is huge. Barring a small number of
companies, India pharma machinery manufacturers I am sure that pharma equipment manufactures in
are only able to achieve meagre amount of exports and collaboration with pharma manufacturer can bring
are able to only achieve sales through domestic supply. latest technology at lower costs with improved
compliance and better quality. This will help to reduce
It is high time that Pharma machine manufacturers dependance on foreign manufacturers and improve
update their skills both mechanical and software to the competitiveness of Indian pharma companies in
international market.

Sanjay Kumar Dasmohapatra to the envisioned Atmanirbhar Bharatby building up
President the pace to grow big in the equipment manufacturing
Technical & Opera ons space by improving its capacities and capabilities to
Medopharm manufacture high end ultra-modern machinery
required by the pharma industry.I am optimistic that
Although the Pharma Machinery sector is contributing with the support of local talents and continuous
to economic growth by generating revenue of Rs.6,000 government initiatives it is for sure that India will
crores with around 800 SMEs where 300+ companies become self-sufficient and self-reliant and definitely
are registered with IPMMA handful of manufacturers will substitute its imports in a big way. Joint initiative of
have set up assembling / manufacturing units locally Indian Pharma Machine Manufacturers and State /
but mostly dependent on overseas partners for Central Government shall not only substantially boost
technical know-how.This sector can substitute the this sector to become Atmanirbhar but also help to
growing imports from foreign countries to contribute emerge as Pioneer to cater the global requirement
with a tag line, 'HighestQuality atAffordable Price'.

06 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org

COVER STORY Rajesh Shah However, there is a long way to go for the envisioned
Founder-Promoter Atmanirbhar Bharat as far as machinery sector is
Maharshi Udyog concerned a there is still a huge dependency on the
imports. Amongst few key reasons why for India is
During these unprecedented times, while the unable to produce technologically advanced & state-
pharmaceutical industry has continued to operate and of-the-art machinery is the import duty on machinery
truly live up to its title as Pharmacy Of The World with which is merely 30%, making it very easy for
exports standing at USD 20 billion+ the country has its companies to import machinery with the kind of profit
immense potential to become the largest exporter margins pharmaceutical companies have.
from the 3rd largest globally currently. With this there Additionally, the government must give due
definitely exist a huge demand for quality processing recognition and encourage pharmaceutical machinery
and packaging machinery. sector to develop and evolve the sector to be capable
of competing with other countries.

Ratan Singhania other countries. On the other side, many players are
Director not taking advantage of cluster formations, EPCG
Singhania Table ng scheme benefits and many more initiatives supported
by government support and this is due to lack of
Import in India is often made by the buyer keeping in awareness of the same.We see a big potential in our
mind ease of getting approvals from USFDA and Pharma Machinery sector for import, substitution of
MHRA, also imported machines are quite advanced. components and tremendous scope in exports as
Currently our machines and technology have to be Chinese products are not performing well. Although
improved for which Government support is needed to they are cheap, they lack after sales support,
put forth some trade barriers to import machines from components supply andcompliance with standards.
Hence, we have very good scope and already Indian
Pharma Machinery are being exported to
100 + countries.

Rajmal Mehta Additionally, ease in export regulations, simple legal
Founder & Chairman protocols for Joint Ventures & tech transfer
Parle Global arrangements will definitely encourage companies to
Technologies Pvt Ltd. invest and develop technologies in India.

As an Indian pharma industry, we should work towards The government can also encourage reliable stockists
trying to get international technologies to India to and distributors from European countries to set up
develop our products. This can be achieved by their manufacturing units in India, this would take us
encouraging joint ventures & utilize strategic real closer of our goal of being Atmanirbhar.At this
partnerships to improve the technologies developed in critical juncture, the world is looking at India as a
India.We hope that the government encourages the reliable and trustworthy source of machinery. We
industry by investing, subsidizing and incentivizing should grab this opportunity with both our hands and
R&D activities. grow at a rapid pace during this setback.

07 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org

COVER STORY Amit Marfa a significant infrastructure investment into roads,
Managing Director consistent electric supply, dedicated manufacturing
Electrolab India Pvt Ltd. ghettos will be required. We import a significant % of
our raw material from all over the world, and while
Precision electronic manufacturing needs to be China may be a smaller proportion, there are some
encouraged if India is to be import independent, components where the cost to switch away from China
as a country of origin is prohibitive in the immediate
future.

C S She y potential even become no. 1 exporter globally.
Founder & Managing Director Entrepreneur should be in comfort while taking care of
Crystal Automa on Pvt Ltd. production and operational activities to run the
company with single window to take care of multiple
The labour policy should be growth oriented liberalized revenue and administrative work. The existing single
policy which will greatly change the scenario to make window system is neither popularized nor seems to be
Atmanirbhar Bharat. There is a vast scope for import effective or utilized by MSME entrepreneur is a matter
substitute, export and domestic business with better to be looked into. Under skill development project
quality of machinery, latest automation facility and more skilled personnel should be trained as per the
infrastructure. India can beat other countries with good right aptitude of the trainee and impart growth-
oriented skills which will help in production and growth
of our country.

Aasif Khan As Indian industrialists we are extremely potent to be
Founder & exporters on a global scale. Collaborative, integrated
Managing Director approach is the need. Few like-minded companies in
Fabtech Technologies same activity come together, Free management
Interna onal Ltd. bandwidth, get economies of integration and you fly.
Be broad minded in thoughts, let the best person lead.
Have proper audits in place for governance. And you
see automatically we start getting there.

Oswin D'Souza while ensuring raw material/parts availability at all
Director times. Also, measure to be taken to increase domestic
Osworld Scien fic sales/exports.We atOsworld do not import fromChina
Equipments Pvt. Ltd and we see no reason why India can't be globally
competitive. We have it all, our great culture of
To become self-reliant, import-independent the focus tolerance, the goodwill, the young workforce, the
should be to improve product quality at reduced costs language advantage, our frugal lifestyle and above all
our greatest asset is our humble beginning.

08 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org

COVER STORY Harish Panchal and automation machines close to the international
CEO standards or even better in some cases. Eventually
Allegro Pharmachem Indian Pharma Industries outlook is changing now and
Equipments Indian manufacturers are preferred compared to
international seller which are almost 10 times
As on today as per the EXIM records, Indian Pharma expensive than Indian machines.We would urge Indian
Industry is import dependent for many items. Many Pharma Industries to share your views/requirements to
Indian Pharma Industries are souring their machines Indian Pharma Machinery Industries helping us to
and equipment from international markets like USA, prove that our machines are better than international
Europe, China, Japan and many other countries. ones. Surely once we all think of giving ultimate
However, now slowly the Indian Pharma Machinery products to our clients, this will be the first step
Industries have started providing quality, technology towards & contributing to the envisioned
Atmanirbhar Bharat.

N.M. Mehta Government end like increase export incentive,
Founder & MD enforce manufacturing regulation law, promote
Newtronic Lifecare business-friendly environment, provide cheap power,
Equipment Pvt Ltd minimize or streamline approvals required to save
time& more.
The Atmanirbhar Bharat gives us a great opportunity
to become self-reliant, but are we ready for it?Well, Government also should improvise on Logistics line
certainly the manufacturers are. However, there are more freight lines, express ways, more ports for
certain changes that need to be done from the shipping and most importantly matching the
guideline from various world pharma bodies of
USFDA, MHRA,TGA,CDSCO, MCC, and more.

Rajendra Khimsaria, Certification of newly developed machine in right
Founder - Director environment. Lastly training programs on
Khimsaria Associates Instrumentation to measure every process in the
operation of machines and Best practices in Design &
IPMMA in partnership with Govt. should set up Quality Assurance with the help of reputed European
Technology centres across India near Pharma Machine agency.Additionally, Centralized Govt. agency can
Manufacturing hub which should assist for Metallurgy undertake regular surveys to gather feedback from
lab in selection, sourcing of appropriate raw materials customers to check the performance of machines
and testing, Testing, Validation, Documentation and exported by respective Pharma Machinery
companies. Penal action to be taken not matching the
set criteria to ensure right branding of Made in India
Machines.

Alpesh Gandhi subsidy, GST, freedom from TDS, and other
Managing Director commercial benefits. Indian Government must invite
Ami Polymer Pvt. Ltd. foreign companies for commencing their operations in
India. Initiative taken by the government for promoting
To become Import independent nation, government Indian pharmaceutical companies to develop
should encourage Indian raw rubber manufacturers by vaccine/drug was commendable.Similarly,
announcing some lucrative benefits on Income-tax, government should also encourage the Indian rubber
Industry and launch some business-friendly schemes
for import independent revolution and for actualizing
the concept of AtmaNirbhar Bharat Abhiyan.

09 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org

COVER STORY Abbas Rupawala Definitely, we see a great deal of potential for Indian
Director pharma Industry to manufacture, import substitution
Rizab Product Pvt Ltd and export globally. We Indians have enough
knowledge coupled with skill & high IQ levels and with
opportunities we can outshine the world. The best
examples are the Indian CEO's heading the big
multinational companies. The need of the hour is to
stop brain drain from India for greener pastures.

Balasaheb Gatkal Industry from Indian Government, certain strategic
Director relaxation on PaymentTerms and BankGuarantees.
Promas Engineers Pvt. Ltd.
From Pharma Industry, Indian companies should keep
From both the Indian Drugs and Pharmaceutical the delivery timelines and penalties expectation in line
manufacturing and Indian Pharma Machineries with the global standards hence supporting each
Industry perspective to achieve the Atmanirbhartawe other.
need to minimize the dependency in terms of importing
raw materials, technology, electronics/softwares etc. Compliance for meeting the USFDA or GMP guidelines
should be dealt with strictly. Otherwisein turn that
In terms of support needed by Pharma machinery results in substandard APIs or Formulations, waste of
resources like electricity, water, may cause
contamination and even unhealthy for human life.

Jhankar Du a reality it needs time and a collaborated effort right
Managing Director from raw material, supply chain, manufacturing,
India Region - delivery to consumers.
B&R Industrial
Automa on Pvt. Ltd. It is essential for consumers to change buying patterns,
manufacturers to changes suppliers amongst many
In thisVUCA world, there is constant and unpredictable more. Thus, throughout the entire value chain there
change and current situation has further added to needs to be a paradigm shift. Indian pharma machinery
uncertainty. A sustainable digitally active ecosystem is manufacturers are self-reliant offering automated
budding to thrive in near future encompassing next machines and lines with sophisticated electronics. The
generation and advanced automation technologies. Indian pharma facilities need to place trust in Indian
machinery manufacturers and embrace the call “Vocal
Firstly, for making the vision Atmanirbhar Bharat, a for Local”. Such approach will motivate machinery
manufacturers as well as boost technology adoptions.

The affirmative surge that Atmanirbhar Bharat has created certainly seems to have seeped in the industry. However, agreeing to
the fact that it's a process of gradual change which needs some concrete steps taking in consideration all the challenges faced and
support needed by the building blocks - the manufacturers. It's time for all stakeholders Pharma machinery sector, Government
and Associations to have close collaboration and coordination to achieve the objective of Atmanirbhar Bharat. IPMMA as a
national body representing Pharma machine manufacturers, weare taking baby steps but firmly inching towards the bigger
mission.

10 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



INTERVIEW Leaders In-Sight

Babulal Singhania, Founder-Director – Singhania Tableting

How has been your journey in Singhania constant updation and improvement and for that it is
Tableting from Individual to company critical to keep abreast of the latest technology and
growth perspective? investing in it. It is equally important to constantly train
your employees and teach them new skills and enrol
In 1968, SinghaniaTableting as a manufacturer of tablet them in courses.
tools started journey with seven employees in a
smallsingle unit and today we have fivefull-fledged Honesty and Transparency: This is the one thing that
manufacturing units with 200+ people. Gradually we will hold you in good stead both with your customers as
realised that there was an immense scope for product well as employees. It will help in building trust and
improvement and we progressed rapidly in that therefore long-term relationships.
direction.We started offering customised selection of
alloy steel to suit different formulations and acquired Where do you foresee India's growth as a nation for
latest machines for manufacturing tools. We collated the Pharma machinery domain?
details regarding wear and tear of the tools from clients
and used those data points to improvise upon our India has tremendous scope in the international
products. Furthermore, we introduced precision market, when it comes to pharmaceutical machinery.
measuring instruments for our tools. In 1988,we added No other country can match Indian talent for their
one more feather in our cap by manufacturing of Tablet sincerity, hard-work and technical qualifications. India
Presses. Today, products by Singhania Tablettingare a already has its presence globally and is increasing its
quality benchmark in the industryand our products footprint in international markets like Europe and
&machines are currently reaching to 60+ countries. USA.We hope to see India as a manufacturing hub for
the pharmaceuticalmachinery in the near future.
What are the three key human and management
qualities that an industry leader must possess? Where does Indian Pharma machinery industry need
to improve in terms of branding and marketing?
Encouraging and Motivating your team: In
ourmanufacturing industry the shop floor workers and Now that India has invested in its technical capabilities
technical team are very critical. If they are given the to come on par with the world, marketing can be the
freedom and flexibility to experiment and make game changer. A couple of decades back, in our
mistakes, they learn and excel at their work. The shop manufacturing industry we have mostly relied on word
floor atmosphere needs to be friendly and open. of mouth publicity and endorsements, however now it
is important to be visible as well. Participation in local
Always Learning: One needs to be in a mode of and international exhibitions, having a technically
qualified marketing team, presence in international
magazines and having sales agents overseas are some
of the steps that can help push the envelope and make
our mark in the International market.

What inspires and motivates you?

We get motivated every time a customer throws up a
unique challenge. It enables us to innovate and come up
with unique solutions. Quality is our biggest driver and
we consistently strive to not only match our products to
international benchmarks, but to even surpass that.
Over the years, some of the technical firsts we have

12 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



INTERVIEW achieved are Hard chrome plating on punches, Tool timely fashion.
Inspection Kit,Tool Polishing Kit,Tools Storage System,
Introduction of Tablet Designing on AutoCAD, CNC Finding trainedpersonnel: Time and effort needs to
Engraving for punches, Tablet Press capacity increased be spent on training every new employee, and one
by introducing higher station turrets, Introduction of A needs to work towards retaining them.
tooling and many more.
Managing cost efficiencies: Despite tooling costs
How would you define personal success, please share remaining more or less the same in the last several
your approach and methodology? years, manufacturers still need to invest heavily in
automation and technical innovations.
Success for me is job satisfaction and customer delight,
and for that I have always believed in investing in R&D, Customer is at the centre of everything we do. Both pre
as knowledge is critical to achieve both. I strongly and post-sales service is equally important. One needs
believe that knowledge needs to be open source and to work with customers constantly to resolve any
hence shared with both arms open. issues they may be facing. For a new product, it could
be R&D like shape, size, design, material, etc. For
From your rich experience of close to 5 decades, what existing products, it involves developing new
were the 3 major challenges you came across in specifications for enhanced performance and
taking Singhania Tableting to the next level and how proposing changes in the future basis of changes in
did you overcome it?What do you see as the Secret of formulation.
Customer Service?
We strive to solve customers' problems and our R&D is
Timely deliveries:Most customers want their products completely based on their feedback and issues. This is
delivered yesterday. In an industry where every order is the only thing, that can leave along-lasting impression
customised and needs to be started from scratch, it is in customers minds and retain us as their go to product
difficult to meet their urgent delivery demands in a and service provider.

The Singhania Team behind the success of Singhania Tableting www.ipmma.org
14 PHARMA PRO & PACK | JULY - SEPTEMBER 2020

think chemical resistant rubber

think 9 star rubber work

We have developed Special Rubber formulation having
Excellent Chemical Resistance to various Chemicals.

Expertise in Platinum Cured Silicone Products, Syringe Piston Seals / ‘O’ Rings, TC Gaskets.

We Manufacture O Rings, X / Quad Rings, Seals & Oil Seals,
Diaphragm with fabric, Rubber Metal bonded parts, Mounts, Gaskets, Grommets, Bellows,
Extrusion,Butterfly valve seals, Customized Rubber products as per Drawing.
All these Products can be manufactured in any of the below mentioned material:-
Nitrile, Neoprene, EPDM, HNBR, Silicone, Fluorosilicone, Hyplon, SBR.
Viton, Poly Acrylic, NBR, Polyurethane (AU, EU) Millable.

We provide our clients with:
Quality products
Prompt delivery

REACH Compliance

Equipped with State-of-art Technology
and Latest Imported Machinery

Dimension Accuracy: +/- 0.02 MM

We Cater service to the following industries:

Chemical Process Industry Pumps Solar Industry
Pharmaceutical Industry Oil and Gas Industry Mechanical Seals
Food & Beverages Industry Compressors

Starred Rubber Moulding Destination

Add : ISO 9001:2015 Certified
Email : [email protected]
A-117, Kushal Mangal Industrial Estate, Tungareshwar Website: www.9starrubberwork.com
Mandir Road, Vasai (East), Palghar - 401210, INDIA.

Contact : +91-9870131313 +91-9892978313 022-28812285

TRIBUTE TO INDUSTRY Wisdom Nuggets by Pharma Luminaries

Dr. Ketan R. Patel Milan R. Patel

Chairman & MD Joint MD

What was the Vision, the thought process Pesticide poisoning was a common occurrence in the
behind startingTroikaa Pharmaceuticals? agricultural districts of India. Besides, many people
attempted suicides by consuming household
From our inception, we have firmly believed that the pesticides. Our product was an antidote that saved and
future is bright only for an innovative drug company. continues to save thousands of lives. This was a turning
This thought process was mainly behind the making of point for the company, and it fueled our drive to make
Troikaa Pharmaceuticals Ltd; probably the only drug products that are difficult to formulate, meaningful to
maker in the country, with utmost focus on innovation society and profitable for the company.
and NDDS (Novel Drug Delivery System).This thought
process drives us looking for newer opportunities and Later, we started with niche products that offered small
corresponding innovative ideas to solve meaningful volumes of business. The ones that big companies did
problems in healthcare through drug delivery. This has not go after, but which were nonetheless essential and
fostered the culture of innovation and creativity at in demand. Our second successful product was an
Troikaa. antidote to Cyanide. Later we followed up with
antidotes for Mercury and other poisons. When the
In the initial years as a startup how did Troikaa scope of antidotes was exhausted, the 90s opened
manage to serve as per client needs and still draw another opportunity with the beginning of cardiac
their own product roadmap? interventions, which required specific injections
imported from either Europe or Australia, and which no
Initially, in view of the lack of resources, we had no Indian player had attempted to produce. We developed
option but to rely on generics for business. However, we a range of five injectables used during and after cardiac
were consistently looking out for a differentiated surgery. From drugs for open-heart surgeries, we
product.And it is as if destiny intervened, a doctor friend moved on with anesthetic agents. All these products,
shared his sadness and frustration at the loss of a patient including antidotes were hospital centric & gave us a
in intensive care due to the lack of availability of a drug presence in high-profile hospitals across India. We then
called PAM injection, which was manufactured by came up with a sales team to build the prescription
Sumitomo Pharma, Japan. It is an antidote to pesticides business for mainstream products.
& frequently used to run out of stock.This incident gave
us an insight that for a small company like ours, there What are the strategies in driving Innovation within
was a substantial market for this drug to generate Troikaa and how were the challenges dealt with?
revenues. We proactively decided to try & develop this
product and in about 18 months we developed the The changeover from reverse engineered generics to
drugPralidoxime and even formulated the injection. We original NDDS happened as soon as we had surplus
marketed it at a very affordable price and managed to resources to venture into research. This change was
substitute the imported product with our brand triggered by a discussion with a doctor who enlightened
Neopam.The uptake on the market was remarkable. All us on the fact that the 3 ml Diclofenac Injections were
major medical colleges started using Neopam Inj. extremely painful. To be told that, a painkiller injection

16 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



TRIBUTE TO INDUSTRY

itself caused a lot of pain and sometimes abscess at the Subsequently, the complete day-to-day functioning is
site of injection was a shocker. It is then that we realized designed to encompass and uphold our values. Further, our
that we could work to improve the drugs already in the Talent Management team instils and continuously reinforces
market.After two years of development work, we came our values through well-defined policies, protocols and
up with a new diclofenac product Dynapar AQ inj operating procedures, regular communication and learning
75mg/ml. It took 2 more years to conduct the and development initiatives.We inspect what we expect on an
pharmacokinetic and clinical studies to establish that ongoing basis and recognize and reward values-centric
our novel diclofenac injection is painless at the site of contributions through a unique 'continuous' Performance
injection, except the pain of the needle prick. It's not Review and Feedback processes. Our values are enshrined in
just this, the ingredients of our formula are so safe that our name.
it can be administered as intravenous bolus injection.
Soon DynaparAQ eclipsed all brands on the market and What did it take for Troikaa to reach a level where the
is today the top selling diclofenac injection in India and accolades include multiple patents under the belt?
several countries. Today, it is Dynapar AQ that is a
reference in the market that 40+ companies copy due to Adhering to each of our values described above, has brought
the weak enforcement of IPR in India. us where we are today. And the strength of these very values
will take us to a bright future.
What was the role ofTalent management in instilling
the core values of the company? What technological shift do you expect in the Pharma
sector postCOVID-19 scenario?
Our Seven Values - Innovation, Perseverance, Honesty,
Humility, Hard Work, Quality and Patriotism -- define We realized that if the company has cloud-based software
Troikaa's core identity. Along with our Vision and functioning in its various departments, team leaders can
Mission, they define “Why” we exist, “What” we believe manage the functioning of their teams even if they work from
in and stand for and “Where” we are heading. We home.There were some creative departments like marketing,
strongly believe that without clear values, both the product management, R&D etc., where work from home
organization and individuals struggle as they will lack cannot produce the requisite output. However, we are
clarity of purpose and direction. exploring new technology platforms and we believe that even
these functions can perform to their optimum if the situation
Our Talent Management initiatives continue to play a demands work from home.All in all, we have started looking at
crucial role in upholding and enhancing our Values and out-of-box solutions, because COVID-19 has taught us that
we begin at theTalentAcquisition stage itself.We select this can happen any time, maybe after 2 years, 5 years or 10
candidates who are aligned to our values through a years.We believe that Cloud Computing and Artificial
comprehensive interviewing & vetting process. Intelligence will play a very significant role in the years ahead.

18 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



TRIBUTE TO INDUSTRY erosion of their generic
drugs due to increased
competition and channel
consolidation in theUS.

On the other side, there has
been a significant rise in the
demand for precision
medicine and other
complex drugs, thus calling
out the need for innovation
in the Indian pharma
industry. Time is ripe for
Indian pharmaceutical
companies to look at novel

How can Indian Pharmaceutical manufacturers drug development in a significant way, as generic drugs
synergize to drive innovation to boost our Indian lose out market due to stiff competition globally.
Pharma Industry on a global scale?
We need to build an innovation-oriented ecosystem on
Indian pharma companies have to look towards the foundations of its distinctive capabilities in key
changing their business model from supplying areas of the value chain, such as manufacturing,
commodities to supplying innovations (patented product development and process innovation. In such
drugs).In March 2020, E&Y report 'Reshaping India into a ecosystem both public and private organizations need
life science innovation hub', it was pointed that Indian to invest in the development of the skills, infrastructure
pharma companies have witnessed significant price and culture to transform Indian life sciences into a hub
for innovation for the world.

20 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



PACKAGING Every innovation has to benet
mankind at large

Chakravarthi AVPS, Global Ambassador, World Packaging comes handy in fulfilling all the above-said
Packaging Organization requirements. It is a fact that India is still a developing
country and so affordable and efficacious drugs are in
As COVID-19 transforms the pharma industry, demand, but this does not deter the accessibility of
packaging, as an integral function, is also evolving to technological advancements to the customers (ex.
meet the new requirements and demands.Chakravarthi Revolution in mobile communication).The pharma and
AVPS, Global Ambassador, World Packaging packaging industries always have great synergies and
Organisation shares insights about the emerging trends consociational relationship. The innovation in each
in pharma packaging, growing role and importance of industry inspires the other to excel. The demand to
this function in driving important gains and benefits optimize the drug delivery for healthcare professionals
such as patient-centricity, and measures to insulate the and patients in today's circumstances is much larger
packaging industry from disruptions like the COVID-19 than ever before. And so, packaging has to innovate
in future. with accelerated R&D efforts to keep up with the
technological advances, remain competitive and not
Pharma packaging providers tackling advanced exceed the regulatory framework.
technology demand challenge owing toCovid-19
Pharma & Packaging industry future trends
Under the current pandemic situation, consumer
behaviour has completely changed in every aspect. The future of the pharma market will be having a
Physical interactions between patients and doctors are targeted market approach rather than a mass-market
declining rapidly.With advanced digital communication model. In fact, we are already seeing these trends
being easily available every corner, consultations are catching up in some segments. Pharma industry's
happening remotely. approach today is more user-centric. Every
development revolves around patient needs because it
Recollecting my recent statement, “Packaging will be is the influencing factor to shape the market. So, self-
your second physician”. It is really apt under today's administered devices with advanced technology,
background. Ease of administration, dosage accuracy, especially for combination drugs which are safe and
dose monitoring, minimizing (zeroing) medication user friendly, are on the rise.
errors will be the key factors, apart from safeguarding
drug efficacy, providing product information while Smart inhalers and nasal sprays will gain more demand.
following regulatory framework. Transdermal patches are currently used for pain relief
and normal healthcare. Similarly, a lot is happening in
oral dissolvable films. This format is very useful for
pediatric and geriatric patients. We have heard that
Gilead Sciences is developing an easier-to-administer
version that can be inhaled for the sought-after antiviral
drug Remdesivir forCOVID-19.

Thus, one cannot deny the role of packaging in the
pharma industry with its rapidly changing needs and
demands from the market. Hence, companies are
accelerating their R&D efforts to meet critical Medicare
requirements too, through this concept.

22 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



PACKAGING Use of Artificial Intelligence in every field will be on the material and technology to many of these developing
rise. Concepts of smart packaging with advanced NFC countries. So I believe the impact will not be so
components may become a norm for certain products. negative.
Evolution of ultra-thin ICs that can be embedded in any
package has given scope for incorporating more Reforms for Pharma Packaging products
features. However, disposal of such packages after use
remains a challenge as they hamper the sustainability I keep saying that unequivocal communication is a
journey. Implantable medical devices gain ground as must at all levels, especially when you are working for
they are very appropriate for regulated drug delivery in an industry that makes products that are life-saving
certain cases. Wearable medical devices is another and life-sustaining. There is absolutely no chance for
segment to watch. Many of them are already finding short cuts at any stage. Adhering strictly to the
their applications, not just for diagnostics and regulations and maintaining perfect documentation is
monitoring purposes but also respiratory, therapeutic not just a requirement but a mandatory norm.
pain management and others. At the end of the day, I
sincerely believe that every innovation has to help That's on the behavioral front. In addition, pharma
mankind get benefited at large. packaging industrialists need to embrace rapidly
changing technologies into their processes and
Pharm products growth: National vs (competitive) packaging innovations to meet the ever-changing
International market demands from the industry. One has to understand
that packaging safety is as important as product safety.
You have to agree, it is all changing dynamics. But think Further, a detailed understanding of the constantly
about India's situation 15-20 years ago. I believe the changing regulatory landscape is always needed to
Indian pharma industry can withstand such challenges produce safe and efficacious packaging. The pharma
as we have the technology and wherewithal to packaging industry has to strictly adhere to the
introduce products like Remdesivir and make them guidelines and standards and it has to happen
available to Indian customers. In this particular case, flawlessly, constantly.
around eight Indian companies are expected to get a
license, as the process for approval is under Source: Express Pharma. Please note that this is an
acceleration. And on the other front, Indian pharma abridge version of the original interview.
packaging industry is a key supplier of machinery,

OBITUARY

IPMMA offers its deepest IPMMA offers its deepest
condolences for the loss of condolences for the loss of

Shri Jayantbhai Vejibhai Khambha a Shri Ketan Karani
(1930-2020) (1974-2020)
CEO
Founder & Chairman
Cadmach Machinery Co. Pvt. Ltd. Amulya Industries

24 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org















REGULATORY COMPLIANCE Conducting Remote FAT (Factory
Acceptance Test) In Pharmaceutical
Industry in a Compliance Way

Varadhraj Vijayakumar Execution of FAT

Associate Manager Factory Acceptance Testing is executed at the vendor's
Biocon Biologics test facility. The FAT document must be written to fully
challenge the Functional Specification (FS) that was
Introduction derived originally from the User Requirements
Specification (URS). The expected regulatory
In the light of current travel restrictions due to the compliance norms must be considered while writing
ongoing COVID-19 pandemic, many of the the FAT protocol.The intimate and detailed knowledge
pharmaceutical companies are either planning or going is required to write the FAT. Site sends their team to the
for virtual Factory Acceptance Test (FAT) for their vendor site for conducting tests and also to get trained
machinery via a live stream or a video conferencing on the machine.
facility.
Writing FAT Protocol: Vendor normally writes this
What is FAT protocol and same shall be reviewed by site team. The
team may recommend additional tests if any and same
The Factory Acceptance Test (FAT) is a process that shall be included in the protocol.
evaluates the equipment during and after the assembly
process by verifying that it is built and operating in RegulatoryView on FAT
accordance with design specifications and as per
purchase order. In the pharmaceutical, biotech and medical device
industries, factory Acceptance test documentation is
FAT Protocol routinely viewed to ensure that all cGMP requirements
are complied with. Requirements that are legislated for
The FAT protocol is an inspection that includes both mainly through CFR Parts11/210/211/820 in the USFDA
static and dynamic exhaustive testing of systems or and in similar legislation throughout the globe.As per
major system components to support the qualification EU Annex 15: Qualification and Validations regarding
of equipment or a system. The tests must verify that all FAT “Equipment, especially if incorporating novel or
functionality detailed in the User Requirements complex technology, may be evaluated, if applicable, at
Specification (URS) is embodied and performs as the vendor prior to delivery”
specified. It is written by the manufacturers and
executed by the client or client representative. Getting Back to Remote FAT and what is Remote FAT?
Remote FAT is based onVirtual way of conducting tests
for the machines at the vendor site.The customer need
not travel thousands of kilometers and lose hours of
traveling time to see their machine run. With remote
FAT, the client can be at a place wherever he or she likes,
watch the running of the machine, discuss important
points with the manufacturer as well as view critical
machine parts running live.

How it's conducted

OEM uses multiple high-quality cameras to give the
best possible view of the machine. Typically, one is
placed where the client can have an overall view of the
entire area. One or two cameras are placed around the

32 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



REGULATORY COMPLIANCE machine to see specific details.On top of that, the panel of instruments, equipment, and more to the rest of the
will be shared for a live view of the results. Manufacturer team. This type of platform is also interactive, allowing
shall be flexible to move each camera according to the the headset wearer to see and talk to the other
customer's needs or specific requests during FAT. participants and pull documents into view, while still
seeing their environment and making smooth
Challenges with Remote FAT operation of factory acceptance test.

Quality impact Aspects, Timelines, Capital/Cost, Remote MachineTraining &TroubleShooting
Resources (both client and vendor),Vendor capabilities,
Contract reviews like Purchase orders etc. The live machine training remotely with virtual training
modules and multiple training sessions is must for
Any specific requirements for the online meeting understanding the operation of the machine. Secondly,
tools? there should be service team who can perform trouble
shooting with remote access to resolve the issues.
There are ample video conferencing tools/platforms
available these days like Webex, Zoom, Google meet or What Pharma companies
Microsoft teams.The meeting can simply be conducted are expected to do in line
with OEM for conducting
Remote FAT:

The virtual/remote FAT
Protocols are to be pre-
approved by quality
assurance team, and the
detailed plan should be
made, so thatQA team can
witness the “real-time”. To
make this, a change
control to be raised along
with risk assessment
detailing the procedure
and the risks involved.

1. Standard operating
procedure should be in
place for Remote FAT.

2. QA team shall have
Quality Vendor
Audit/review of QMS
for conducting remote
FAT procedures of

with a link shared by the manufacturer. The only vendors. Assessment of vendor training on the
requirement is to have a laptop, desktop, tablet or
mobile phone with good internet connectivity, a Project pre-requisites procedures (FAT Plan,
microphone and a speaker.
Punch list Plan,GDP Plan) byQATeam.
Advanced features like by using HighTechGlasses 3. Document Handling: Vendor should have a

The on-site manufacturer user, can wear the Virtual controlled copy of the FAT issued via Document
Smart Glasses, which can go hands-free while they
move through the environment, projecting their view Control or by SCAN copies after approval by site

QA team.
4. Signature log of Vendor and site team for their

presence physically equipped to execute the FAT

34 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



REGULATORY COMPLIANCE (live video play-back, hand held cameras etc. and What can be done for the FAT proofs?
daily log sheet)
5. Timelines: Prior to this pandemic the timelines It can be requested, and same can be recorded while
scheduled by the Team needs to be relooked performing the remote FAT and once its complete, the
because the FAT durations will be same in some video films to be sent by e-mail or any other suitable
cases and may exceed also due to the FAT's now means along with the dispatch of machine.
being performed remotely.
6. From cost perspective, for the site team its cost- The OEM should train the site team for tools, technical
effective as it saves travel costs for 3-4 team capability, safety systems and IT capability. The daily
members. However,document generation, time, punch list should be sincerely followed by vendor and
internet connectivity, accessories will cost site team both.Efficient project review includes good
considerable from both vendor and the site team. rapport with the purchase team with all relevant mails
and MOM'swell documented.
However, in this case Purchase order needs to be
balanced from both OEM and site team, which is CONCLUSION
different from the original project scope.
Due to this ongoing pandemic, the necessity of doing
InitialTraining FAT remotely has arisen. However, as a Project, all FAT
testing procedure if it is summarized in the FAT report
OEM Shall guide the site team, because everyone in the with detailed punch list, Minutes of meetings and with
site is not as trained or experienced with this remote appropriate execution in a traceable manner, will have
FAT. Hence prior to beginning Remote FAT, initial greater effect on leveragability in tests and this will lead
training shall be imparted to the site team with respect to a successful remote FAT.
to the accessories, and tools while handling.

Training aspects should include technical capabilities,
safety systems, IT systems, hardware and software to
be used.

Daily Punch list

The punch listing for normal FAT and remote FAT
should not change. The FAT Team should follow the
same approved procedure and this should be followed
by vendor also.

Project Review

Close review of project documents is required with the
vendor to ensure a smooth remote FAT, instead of
dragging many things with respect to purchase order.
Hence good connection with purchase team is needed
in all mails or in telecon discussions. Minutes of
meetings for all discussions are to be shared every day
and same shall be documented.

Limitations of Remote FAT

Controls exist with the testing engineer, Internet
connectivity between Onsite test engineers and
receiver site, Communication gap between engineer
and receiver due to language barrier, finally with time
zone between different countries.

36 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



IPMMA NEWS WEBINAR Expert Talk:
The Future of Pharma Machinery

This webinar was one-
of-a-kind webinars for
Future of Pharma
Machinerythat hosted guests
and speakers from Pharma
industry, Pharma machinery
industry as well
representative from
Government of India. This
webinar held on 11thSept
2020 was organized by IRM
group, Cadila
Pharmaceuticals and

supported by IPMMA. After a unique and warm welcome with a poetic flavor from IRM team, following eminent personalities
shared their knowledge and experience about future of pharma machinery as guest speakers.The webinar was ably moderated
by Kaushik Desai,Advisor IPMMA.

Johnson Mathew,CHRO IRM group

A warm welcome to all the esteemed panelists and participants on behalf of IRM group and Cadila
Pharmaceuticals with a special regards toChairman and Managing Director Dr Rajiv Modi.

Kaushik Desai,Advisor IPMMA

Covid-19 pandemic has brought out unique challenges, pharma machinery sector being the lifeline of
industry for their manufacturing activities has undergone radical change in support and working for
pharma industry. Particularly to ensure that minimum interruption and disruption for supply of
medicines.The pandemic has brought the importance of automation and digitization to the forefront.
The technology that is going to disrupt pharma manufacturing are 3D printing, continuous
manufacturing, digitization and automation, an era of Pharma 4.0 is evolving.

Navdeep Rinwa, Joint Secretary, Policy Medical Devices, Schemes &
Pricing, DoP,GOI(ChiefGuest)

Mr. Rinwaji expressed his happiness to join the webinar and also mentioned that this is for the first time
DoP fromGovernment is participating in discussion on importance of pharma machinery sector.As per

the guidelines laid on 27 July 2020, Government has introduced four new schemes: Two schemes each for bulk drugs and
medical devices and bulk drug parks in India with the help of state government.And we have brought out two production
linked incentive schemes on bulk drug and medical devices each whereby selected companies are eligible for financial
incentives based on their sales. Under this, 5% of financial incentives would be given on sales for 5 years and companies
would be selected based on a transparent criterion and 3,420Cr. has been earmarked for this scheme.

Even in case of medical devices, we havemore than 85% dependent on imports in 2018-19, hence we decided to give
incentives on high technology devices.We are getting encouraging response from both bulk drug and medical device
sectors.With more concrete inputs we would be able to come up with PLI schemes for pharma machinery industry also.

38 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



IPMMA NEWS WEBINAR Mahendra Mehta, President IPMMA (Guest of honour)

All of us are waiting for covid-19 vaccines to resume back to normalcy. Indian pharma industry is known
as Pharmacy of the World and rightly so, many of the pharma companies took up the challenge for
supplying medicine across the globe. Our members had to risk themselves to support the industry for
continuous running of the equipment to ensure timely supply of the medicines. I would like to thank to
all our machine manufacturers to extend their support during lockdowns for continuous production of
medicines.The pandemic will not last forever and I'm hopeful that India will come out as a winner with
join efforts between the government, pharma industry, machinery manufacturers and stakeholders.

Amit Doshi –COO, Karnavati Pharma Machinery

Service is a large aspect and we have to manufacture machinery which requires minimal servicing. Now
since in-person servicesare unlikely, we need to design machines which can communicate with the
manufacturer and user. Refurbishment is a huge market to be tapped, and I think if the manufacturers
and sellers get together and find a market for this, there's huge potential available. I believe for
futuristic approach;we have to understand the customer much deeper.There is need to make machines
which runs with minimum servicing and mass production capability at lower cost.

Aasif Khan – Director FabtechTechnologies

While the machineries are getting developed, and becoming more intelligent, along with that the
overall infrastructure should also become agile. As we move towards implementation of new
technologies like continuous manufacturing and Pharma 4.0, many of the pharma manufacturers are
going to be under increased pressure to adopt new manufacturing method within a legacy plant
environment. Going ahead, all of us in India have to move towards modules which are pre-fabricated
pharma facilities for agile pharma facilities.

ArshiAyubZaveri,CEOTrust withTradeGroup &Sr.AdvisorGovt ofUAE

We are hopeful that in next 30 years UAE would be self-sufficient not manufacturing 10% of their need
but competing also. The sales of pharmaceuticals are expected to forecasted upon to $3.8 Bn in
2021.Accelerated drug registration system, investments in R&D, Innovation and technological
development has led to a rise in the number of international pharma companies and more growth is
projected in near future.

ArvindThakker, DirectorStallion group of companies

Pharma packaging is now ensuring vital role for patients' safety carrying information related to the
product, ensuring tamper evident, traceability and more. From drug manufacturing perspective
human error cannot be overlooked hence automation plays a key role, again ensuring meticulous GMP
compliance is a must.Weneed to adopt risk-based approach for maintenance, probably digitized
maintenance. Total Preventive maintenance and predictive maintenance should be robust enough to
produce quality products batch after batch consistently.

40 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



IPMMA NEWS WEBINAR ShankarGupta, President &COOACGWorldwide

Now industry is getting used to remote working which hints building on Industry 4.0.And Industry 4.0 is
not just digitization as we see, its more about becoming agile while machines help us to make decisions
and also sharing with the customers. Whether its installation commissioning, breakdown
maintenance, we are gradually moving towards remote working. Going forward, IIoT will be the drivers
for the industry.Through digitization we can support customers in terms of cost optimization bringing
in the competitive spirit and further fueling the environedAtmanirbhar Bharat.

AnuvratSingal, MDGlatt India Engineering Pvt Ltd.

During this pandemic there has been a paradigm shift from serial manufacturing to parallel
manufacturing.With serial manufacturing we were looking at bulk production and mass penetration of
the products however with parallel manufacturing customers are expecting completely different
production with the aid of agile framework. Push towards training the workforce, the millennials who
have more inclination towards digitization through AR, AI and more would take us closer to our
common aim ofAtmanirbhar Bharat.

HarshitShah, Director Maharshi group of companies

As per 2017 PWC reports, market size of counterfeit business ranges from approximately $163-217
bnannually. This results in 1 million deaths annually. Huge investments are made into R&D for best
design practices in the packaging sector. Anticounterfeit labels are widely used with various features
which includes micro-text, UI inks, temperature sensitive ink, special invisible fibersand more. All these
security solutions can be deployed by a pharma packaging company depending on their product,
regulation and requirement. In making Atmanirbhar Bharata reality soon, automation will play a
significant role and the faster we catch up and also be at par with the European standardssooner we'll be
self-reliant.

HashadhiWewalage, Director Exploreolgy Pvt LtdSrilanka

Earlier we were having issue manufacturing Warfarin tablets which is used for blood clot that could
result into heart attack. Now we are manufacturing Warfarin with local supplier State Pharmaceutical
Manufacturing Cooperation (SPMC). We were not able to procure good quality these tablets hence we
started manufacturing on our own.There is an opportunity for pharma machinerysector and SPMC has
planned to manufacture 26 products.

Ravindra Pandey,Sr.VPAlembic Pharmaceuticals Ltd.

As rightly put India is the Pharmacy of theWorld and we have to win the confidence around the globe to
supply the reliable solution. Basic pharmacy education should also change to bring this
confidence.Simplification would be the key going ahead, not complex things, which a common man
cannot understand. FromAtmanirbhar Bharatperspective our focus should be more than self-reliance,
even supplying to other countries. With simplicity and reliability as the key factors for our solutions, we
can not only suffice to meet our demands but globally too.

42 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org



IPMMA NEWS WEBINAR S. Joganathan Ravindra Pandey, General Manager, AHS Laboratory
Supplies, Malaysia

Malaysian Pharma industry has key focus on Industry-Academiabridging.In Malaysia we have 263
licensed andGMP compliant manufacturers.The Malaysian Pharmaceutical industry has the capability
to produce almost all dosage forms including sterile preparations, soft gel capsules and very soon high
potency API drugs. We have very trade friendly policy in Malaysia, attractive trade and incentives in
terms of tax cuts and reinvestments, we have dedicated manufacturing hubs, all of this are supported
by highly skilled local talent through our universities.

RishalShah, MD JeksonVision Pvt Ltd.

High speed, low cost, user friendliness, high efficiency, low downtime, reliable, data analytics, these
are the few key points which are going to be part of the basic specification of any product. From pharma
industry perspective, these pointers are much more critical. With seamless alignment of human-
machine intelligence we are looking forward for smart products. Smart machines with high reliability
would be the key for our self-reliance as Indian Pharma Industry.

EndrewTanemaru,VP PTTamaru Mitrasejati, Indonesia

Due to widespread Covid-19 in Indonesia we had multiple challenges primarily in communicating with
customers. Hence now marketing online is the need of an hour to reach out to customers. During this
pandemic there has been a surge in the requirements of customized machines. In Indonesia, for
pharmaceutical machinery development, people are focusing more on local suppliers. Due to mobility
limitations we are managing our operations locally within Indonesia.

Dinesh Patel,SrVPCadila Pharmaceuticals Ltd.

The common man who is buying medicine relies on the pharmaceutical company, so does the pharma
company rely on the pharma equipment manufacturing companies. Reliability is based on two factors
namely: Asset availability and reduction in the maintenance cost.We've designed some KPIsacross the
facility to monitor and improve reliability. The KPI is extensive including business KPI, equipment
availability, quality, process energy saving and more.Deploying advanced digital technologies like
Artificial Intelligence can help us be at par with European standards and companies making us more
self-reliant.

Mohan Kolhatkar, President IRMEPL - Karnavati Pharma Machinery
division concluded the insightful webinar with the vote of thanks to all panelists, moderator,

the organizer Johnson Mathew, CHRO IRM group, and all the participants.

VISIBILITY h ps://bit.ly/3gxL5cb
GIVES CREDIBILITY
www.ipmma.org
We invite all our esteemed members
to leverage our IPMMA LinkedIn
presence to get more visibility

44 PHARMA PRO & PACK | JULY - SEPTEMBER 2020



IPMMA NEWS Resurgence of Indian Pharma

A report of a webinar organized by Inspire Ind in association with Kotak
Mahindra Bank and supported by IPMMA held on 21 Aug 2020

In this webinar special invited Kaushik Desai Mr. Rahul Guha - MD & Partner
speakers were Advisor - IPMMA The Boston Consulting Group

Mr. Rahul Guha - MD & Partner, Mr Sunil Daga & Mr Ashish Desai representing
The Boston Consulting Group Working capital & BL vertical at Kotak Mahindra Bank

Mr. Kaushik Desai - Advisor,
IPMMA and

Mr Sunil Daga & Mr Ashish Desai
representing Working capital & BL
vertical at Kotak Mahindra Bank

In the recent light of the pandemic, pharma has
emerged as a savior in these testing times to provide
uninterrupted supply of much needed medicines. And
from an industry perspective, Indian Pharma has yet again
proved itself and is well-known as Pharmacy of the World.
This webinar covered how Pharma can upscale, navigate
and be on its path to becoming a Global Leader and views
from industry experts on the recent initiativeAtmanirbhar
Bharat.

Mr Sunil Daga and Mr Ashish Desai representing Working capital & BL
vertical at Kotak Mahindra Bank shared their views:

Kotak Mahindra bank offers 4 key services: Pharma spend for every Indian is
Banking solutions, Risk Coverage comparatively low as compared to other
solutions, Digital Solutions and Funding countries and as income level rises in a
solutions which can support growth of Indian country the pharma spending capacity is
Pharma industry. bound to grow.

46 PHARMA PRO & PACK | JULY - SEPTEMBER 2020 www.ipmma.org